ADMA Biologics, Inc. (ADMA) — Fair Value Analysis

Base-case fair value (P50): $11.06 · Current price: $9.47 · Verdict: Undervalued

The Verdict on ADMA

Based on our comprehensive Monte Carlo simulations, ADMA BIOLOGICS INC (ADMA) is currently assessed as Fairly Valued. The analysis indicates a median fair value (P50) of $11.06, positioning it comfortably against its current trading price of $9.47. This suggests that while there is an implied +16.8% to the P50 target, the market price largely reflects ADMA's intrinsic value, aligning with the "Fairly Valued" verdict. Our models project this fair value by evaluating thousands of potential future scenarios, providing a probability-weighted assessment rather than a single point estimate.

How ADMA stacks up against Healthcare

ADMA operates within the Healthcare sector, a dynamic environment where operational and financial health are critical. Our quality tier assessment pegs ADMA as average when compared to its sector peers. This signifies a balanced operational and financial profile, neither significantly outperforming nor underperforming the broader Healthcare landscape. The current price of $9.47 relative to the median fair value of $11.06 further reinforces this "Fairly Valued" stance, indicating that its average quality is appropriately priced into the stock, reflecting the +16.8% potential.

What this means for investors

Investors considering ADMA should note the "Fairly Valued" verdict, meaning the stock is trading close to its intrinsic worth. While the Monte Carlo simulation points to an +16.8% opportunity toward our P50 target of $11.06, significant over or undervaluation is not indicated at the current $9.47. For those seeking a deeper dive, understanding the full distribution of outcomes, including more aggressive bull-case scenarios and conservative bear-case scenarios, is crucial. Sign up for a free FairCurve account to see the full bear/bull distribution and track ADMA's fair value as new fundamentals are released.